For years I filed inflammation under “the enemy,” the thing you douse with ibuprofen and wish away. So when the headlines announced scientists had found the body’s hidden switch to shut it down, the easily-impressed part of my brain lit right up. Then I read what actually happened to the 49 healthy men who got the drug. Their pain faded a little faster, one population of immune cells shrank, and the redness, the heat, the swelling, every visible sign we actually point to and call inflammation, barely moved.

FOLLOW THE MONEY
Bracken and Gilroy have filed a US patent application for using GSK2256294 to treat chronic inflammatory disease.
The two lead authors hold a financial stake in the compound they studied. Source: Nature Communications, competing interests statement, 2026
An off switch that leaves the light on.

The headline promised an off switch. The study described something smaller and stranger, and I could not stop poking at the space between the two.

The work comes out of University College London, led by Dr. Olivia Bracken and Professor Derek Gilroy, published in Nature Communications and picked up this week under the irresistible framing of an inflammation “off switch.” What the team was really chasing is a class of molecules I’d honestly never given a second thought: epoxy-oxylipins, tiny fat-derived signals your body makes and then destroys almost immediately. An enzyme called soluble epoxide hydrolase, sEH for short, is the shredder, breaking these fats down about as fast as they appear. Block the shredder, and the fats pile up. The question is deceptively simple: if you let them pile up, what do they do?

The researchers didn’t reach for a fresh molecule to find out. They pulled a drug off the shelf. GSK2256294 is a selective sEH inhibitor that GlaxoSmithKline ran through early trials years ago in smokers and people with COPD, chasing benefits to blood-vessel function. It was well tolerated, it shut down sEH activity almost completely at higher doses, it nudged vascular function in the right direction, and then it more or less went quiet without becoming a marketed product. This study is its second act.

To test it, the team built a tidy little model of controlled inflammation: a jab of UV-killed E. coli into the skin, which reliably produces a small, self-resolving flare. Two groups of healthy young men, one dosed with 15 mg of the drug two hours before the injection, the other dosed four hours after. Then they watched the immune cells pour into the blood and the tissue.

This is the beat that made me sit up. What changed wasn’t the flare, it was the fate of a single cell. Monocytes, the roving cleanup crew of the immune system, don’t all stay the same: during inflammation, “classical” monocytes mature into an “intermediate” type that has been linked to the chronic, grinding inflammation of diseases like arthritis. The piled-up fat molecule, one called 12,13-EpOME, stepped into that maturation step and stalled it. Fewer classical monocytes graduated into the inflammatory intermediate form.

Wait, why would a fat molecule get a vote in what an immune cell decides to become? That’s the question I couldn’t put down, and the answer is the genuinely elegant part. The team traced it to p38 MAPK, the signaling protein inside the monocyte that acts like the green light for that transition. The fat sits on it and dims it. To show the pathway was actually doing the work, they dosed a separate set of volunteers with losmapimod, a drug that blocks p38 head-on, and got the same drop in intermediate monocytes. Same brake, different lever, same result. I wish more studies bothered to close the loop that cleanly.

So the mechanism is elegant. Now the cold water.

This is where the story the headlines told and the study that was actually run part ways. It was not a randomized, placebo-controlled, blinded trial: the untreated participants got no placebo, and the whole thing was open-label. Forty-nine men, all healthy, all between 18 and 50, split into groups of a dozen or so, with some analyses resting on as few as five people. That’s a mechanistic experiment in fit young volunteers, not evidence that a drug treats a disease. And the effect on the inflammation itself was, by the authors’ own account, almost nothing. Local temperature peaked the same. The swelling didn’t budge. The redness didn’t overtly change. Except for pain, they write, sEH inhibition “did not significantly alter the clinical features.” An off switch that leaves the light on.

There’s one more line worth reading, buried where these lines always are, in the competing-interests statement. Bracken and Gilroy have filed a US patent application for using GSK2256294 to treat chronic inflammatory disease. I don’t say that to smear careful scientists doing careful work, and the funding here came from Versus Arthritis, the BBSRC, the MRC, and the US NIEHS, not a pharma marketing budget. But a patent is a financial stake in the story being big, and “hidden switch that shuts down inflammation” is exactly the size of story that turns a shelved compound into an asset. When the framing runs that far ahead of a 49-person open-label result, it’s fair to ask who the framing serves.

What I keep circling back to is that the sober version is the better one. The immune system doesn’t have a single master switch, and the fantasy that it does is how we ended up with blunt drugs that suppress everything and leave you wide open to infection. A natural fat signal that nudges one cell type off its inflammatory path without shutting down your defenses is subtler than an off switch, and to me it’s more hopeful. It’s also a lead worth chasing into a proper randomized trial, in people who are actually sick, before anyone reaches for the word “cure.”

So here’s my view. I’m genuinely excited to see where the epoxy-oxylipin story goes, and I’ll be reading the next paper the day it drops. But I would not take a shelved sEH inhibitor on the strength of a headline and 49 healthy men, and if my own doctor floated it for something chronic, I’d ask to see the randomized data first, out loud, and I would wait.

Sources

  1. Nature Communications – Bracken, Gilroy et al., “Epoxy-oxylipins direct monocyte fate in inflammatory resolution in humans” (2026)
  2. PMC full text – same paper, open access (design, monocyte and pain results, mechanism, funding, competing interests)
  3. ScienceDaily – “Scientists discover a hidden switch that shuts down inflammation” (Sept 2026)
  4. UCL News – “Scientists discover natural ‘brake’ that could stop harmful inflammation” (funders, framing)
  5. British Journal of Clinical Pharmacology – Lazaar et al., phase I safety/PK of GSK2256294 (2016)
  6. American Journal of Respiratory and Critical Care Medicine – GSK2256294 in smokers and COPD, vascular function
  7. ClinicalTrials.gov – NCT01762774, early GSK2256294 dosing study in overweight smokers